LLY has been the topic of several other reports. Credit Suisse Group upgraded Eli Lilly And Co from an underperform rating to a neutral rating in a research report on Wednesday, October 31st. ValuEngine downgraded Eli Lilly And Co from a buy rating to a hold rating in a research report on Tuesday. JPMorgan Chase & Co. set a $123.00 price objective on Eli Lilly And Co and gave the company a buy rating in a research report on Friday, October 5th. Bank of America boosted their price objective on Eli Lilly And Co from $90.00 to $94.00 and gave the company a neutral rating in a research report on Wednesday, July 25th. Finally, Cantor Fitzgerald set a $100.00 price objective on Eli Lilly And Co and gave the company a buy rating in a research report on Tuesday, July 24th. Nine research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The company has an average rating of Buy and a consensus target price of $111.19.
Shares of Eli Lilly And Co stock opened at $112.21 on Tuesday. Eli Lilly And Co has a 52 week low of $73.69 and a 52 week high of $116.61. The stock has a market capitalization of $113.74 billion, a PE ratio of 26.22, a price-to-earnings-growth ratio of 1.69 and a beta of 0.29. The company has a current ratio of 1.40, a quick ratio of 1.09 and a debt-to-equity ratio of 0.79.
The company also recently announced a quarterly dividend, which will be paid on Monday, December 10th. Investors of record on Thursday, November 15th will be given a $0.5625 dividend. The ex-dividend date is Wednesday, November 14th. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.01%. Eli Lilly And Co’s dividend payout ratio is currently 52.57%.
In related news, major shareholder Eli & Co Lilly sold 700,000 shares of the business’s stock in a transaction dated Tuesday, November 6th. The stock was sold at an average price of $14.00, for a total value of $9,800,000.00. Following the sale, the insider now directly owns 3,148,647 shares in the company, valued at $44,081,058. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Lilly Endowment Inc sold 174,696 shares of the business’s stock in a transaction dated Wednesday, October 17th. The stock was sold at an average price of $113.25, for a total value of $19,784,322.00. Following the completion of the sale, the insider now owns 119,005,804 shares in the company, valued at $13,477,407,303. The disclosure for this sale can be found here. Insiders sold 1,881,684 shares of company stock worth $133,274,076 over the last quarter. 0.11% of the stock is owned by company insiders.
Several large investors have recently bought and sold shares of the stock. Integrated Wealth Concepts LLC purchased a new stake in Eli Lilly And Co during the second quarter valued at approximately $103,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors purchased a new stake in Eli Lilly And Co during the second quarter valued at approximately $114,000. Legacy Advisors LLC raised its position in Eli Lilly And Co by 118.0% during the second quarter. Legacy Advisors LLC now owns 1,354 shares of the company’s stock valued at $116,000 after purchasing an additional 733 shares during the period. Fort L.P. purchased a new stake in Eli Lilly And Co during the second quarter valued at approximately $121,000. Finally, Welch Group LLC purchased a new stake in Eli Lilly And Co during the third quarter valued at approximately $123,000. Institutional investors own 76.17% of the company’s stock.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Read More: Earnings Per Share (EPS) Explained
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.